{"transactions":[{"id":1472347,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T16:15:08.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.15,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-24-017820","document":"form4-06212024_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000141588924017820/form4-06212024_040605.xml","form_type":"4"}},{"id":1845527,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T16:37:32.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2024, subject to the Reporting Person's continuous service as of such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.31,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-039417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919123039417/doc4.xml","form_type":"4"}},{"id":1938137,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-03-27T19:59:08.000Z","date":"2023-03-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1429,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christy Shaffer's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christy Shaffer's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christy Shaffer's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christy Shaffer's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1429},"source":{"system":"sec-edgar","filing":"0001209191-23-021306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919123021306/doc4.xml","form_type":"4"}},{"id":1938136,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T19:59:08.000Z","date":"2023-03-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":1429,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christy Shaffer's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."}],"balance_after":1429,"source":{"system":"sec-edgar","filing":"0001209191-23-021306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919123021306/doc4.xml","form_type":"4"}},{"id":2222298,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T16:28:21.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2023."}],"balance_after":30000,"derivative":{"exercise_price":1.62,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-039240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919122039240/doc4.xml","form_type":"4"}},{"id":2245375,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-03T17:39:30.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock, subject to the reporting person's continued status as a service provider to the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of\nits stockholders, subject to the reporting person's continuous service to the issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-034262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919122034262/doc4.xml","form_type":"4"}},{"id":2245374,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T17:39:30.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of\nits stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":20000,"derivative":{"exercise_price":0.984,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-034262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919122034262/doc4.xml","form_type":"4"}},{"id":2672390,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T17:32:07.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 10, 2022."}],"balance_after":25000,"derivative":{"exercise_price":3.11,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-039949","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919121039949/doc4.xml","form_type":"4"}},{"id":2681311,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-06-04T18:33:12.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.07,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-038379","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919121038379/doc4.xml","form_type":"4"}},{"id":3020899,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-09-29T16:42:21.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":151146,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Hatteras Venture Partners IV SBIC, L.P. (\"HVP IV SBIC\"). Hatteras Venture Advisors IV SBIC, L.L.C. (\"HVA IV SBIC\") is the general partner of HVP IV SBIC. The managing members of HVA IV SBIC include: Robert Ingram, Douglas Reed, Clay Thorp, John Crumpler and Kenneth Lee. These managing members share voting and dispositive power over the securities directly held by HVP IV SBIC. The Reporting Person is a partner of Hatteras Venture Partners and disclaims beneficial ownership of the securities held by HVP IV SBIC except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":151146},"source":{"system":"sec-edgar","filing":"0001209191-20-052343","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919120052343/doc4.xml","form_type":"4"}},{"id":3020898,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-29T16:42:21.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":1242120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Hatteras Venture Partners IV SBIC, L.P. (\"HVP IV SBIC\"). Hatteras Venture Advisors IV SBIC, L.L.C. (\"HVA IV SBIC\") is the general partner of HVP IV SBIC. The managing members of HVA IV SBIC include: Robert Ingram, Douglas Reed, Clay Thorp, John Crumpler and Kenneth Lee. These managing members share voting and dispositive power over the securities directly held by HVP IV SBIC. The Reporting Person is a partner of Hatteras Venture Partners and disclaims beneficial ownership of the securities held by HVP IV SBIC except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1242120},"source":{"system":"sec-edgar","filing":"0001209191-20-052343","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919120052343/doc4.xml","form_type":"4"}},{"id":3020897,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2020-09-29T16:42:21.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":193224,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Hatteras Venture Partners IV SBIC, L.P. (\"HVP IV SBIC\"). Hatteras Venture Advisors IV SBIC, L.L.C. (\"HVA IV SBIC\") is the general partner of HVP IV SBIC. The managing members of HVA IV SBIC include: Robert Ingram, Douglas Reed, Clay Thorp, John Crumpler and Kenneth Lee. These managing members share voting and dispositive power over the securities directly held by HVP IV SBIC. The Reporting Person is a partner of Hatteras Venture Partners and disclaims beneficial ownership of the securities held by HVP IV SBIC except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":193224},"source":{"system":"sec-edgar","filing":"0001209191-20-052343","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919120052343/doc4.xml","form_type":"4"}},{"id":3020896,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T16:42:21.000Z","date":"2020-09-29","kind":"purchase","acquired":true,"shares":18750,"price":16,"value":300000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Hatteras Venture Partners IV SBIC, L.P. (\"HVP IV SBIC\"). Hatteras Venture Advisors IV SBIC, L.L.C. (\"HVA IV SBIC\") is the general partner of HVP IV SBIC. The managing members of HVA IV SBIC include: Robert Ingram, Douglas Reed, Clay Thorp, John Crumpler and Kenneth Lee. These managing members share voting and dispositive power over the securities directly held by HVP IV SBIC. The Reporting Person is a partner of Hatteras Venture Partners and disclaims beneficial ownership of the securities held by HVP IV SBIC except to the extent of her pecuniary interest therein, if any."}],"balance_after":1605240,"source":{"system":"sec-edgar","filing":"0001209191-20-052343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919120052343/doc4.xml","form_type":"4"}},{"id":3020895,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T16:42:21.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":1586490,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Hatteras Venture Partners IV SBIC, L.P. (\"HVP IV SBIC\"). Hatteras Venture Advisors IV SBIC, L.L.C. (\"HVA IV SBIC\") is the general partner of HVP IV SBIC. The managing members of HVA IV SBIC include: Robert Ingram, Douglas Reed, Clay Thorp, John Crumpler and Kenneth Lee. These managing members share voting and dispositive power over the securities directly held by HVP IV SBIC. The Reporting Person is a partner of Hatteras Venture Partners and disclaims beneficial ownership of the securities held by HVP IV SBIC except to the extent of her pecuniary interest therein, if any."}],"balance_after":1586490,"source":{"system":"sec-edgar","filing":"0001209191-20-052343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919120052343/doc4.xml","form_type":"4"}},{"id":3104487,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T16:39:35.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 18, 2021."}],"balance_after":25000,"derivative":{"exercise_price":2,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-037952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919120037952/doc4.xml","form_type":"4"}},{"id":3480276,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-24T16:38:23.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2020."}],"balance_after":20000,"derivative":{"exercise_price":1.07,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-038778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919119038778/doc4.xml","form_type":"4"}},{"id":3886225,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-21T17:21:39.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019."}],"balance_after":11250,"derivative":{"exercise_price":10.74,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001209191-18-038986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919118038986/doc4.xml","form_type":"4"}},{"id":4144486,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-04T17:06:30.000Z","date":"2017-11-30","kind":"other","acquired":true,"shares":995,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Advisors V, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In-kind distribution from L2 Ventures, LLC to its members, including Hatteras Venture Advisors V, LLC, without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is one of the general partners of Hatteras Venture Advisors V, LLC, which is the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by Hatteras Venture Advisors V, LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein."}],"balance_after":995,"source":{"system":"sec-edgar","filing":"0001209191-17-063617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117063617/doc4.xml","form_type":"4"}},{"id":4144485,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-04T17:06:30.000Z","date":"2017-11-30","kind":"other","acquired":false,"shares":99513,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By L2 Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In-kind distribution from L2 Ventures, LLC to its members, without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is one of the general partners of Hatteras Venture Advisors V, LLC, which is the general partner of L2 Ventures, LLC (\"L2 Ventures\"). L2 Ventures is the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by L2 Ventures. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-063617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117063617/doc4.xml","form_type":"4"}},{"id":4232665,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-16T08:24:04.000Z","date":"2017-08-15","kind":"purchase","acquired":true,"shares":1100,"price":7,"value":7700.0,"ownership":{"direct":true},"balance_after":4400,"source":{"system":"sec-edgar","filing":"0001209191-17-049107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117049107/doc4.xml","form_type":"4"}},{"id":4257825,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-13T19:39:03.000Z","date":"2017-07-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in thirty-six monthly installments at the end of each successive month following July 11, 2017, subject to the Reporting Person's continued service as a director."}],"balance_after":20000,"derivative":{"exercise_price":15.55,"expiration_date":"2027-07-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-045115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117045115/doc4.xml","form_type":"4"}},{"id":4264952,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-05T16:36:55.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":2632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 30, 2018."}],"balance_after":2632,"derivative":{"exercise_price":9.11,"expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":2632},"source":{"system":"sec-edgar","filing":"0001209191-17-043392","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117043392/doc4.xml","form_type":"4"}},{"id":4273622,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-23T16:35:38.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":8618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2018."}],"balance_after":8618,"derivative":{"exercise_price":8.81,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":8618},"source":{"system":"sec-edgar","filing":"0001209191-17-041668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117041668/doc4.xml","form_type":"4"}},{"id":4306657,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-05-24T19:59:52.000Z","date":"2017-05-22","kind":"exercise","acquired":false,"shares":126212,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's\nFifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's\nFifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is one of the general partners of Hatteras Venture Advisors V, LLC, which is the general partner of L2 Ventures, LLC. L2 Ventures, LLC is the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by L2 Ventures, LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42070},"source":{"system":"sec-edgar","filing":"0001209191-17-035155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117035155/doc4.xml","form_type":"4"}},{"id":4306656,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2017-05-24T19:59:52.000Z","date":"2017-05-22","kind":"exercise","acquired":false,"shares":172331,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's\nFifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's\nFifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is one of the general partners of Hatteras Venture Advisors V, LLC, which is the general partner of L2 Ventures, LLC. L2 Ventures, LLC is the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by L2 Ventures, LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":57443},"source":{"system":"sec-edgar","filing":"0001209191-17-035155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117035155/doc4.xml","form_type":"4"}},{"id":4306655,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-24T19:59:52.000Z","date":"2017-05-22","kind":"exercise","acquired":true,"shares":99513,"ownership":{"direct":false,"nature":"By L2 Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's\nFifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is one of the general partners of Hatteras Venture Advisors V, LLC, which is the general partner of L2 Ventures, LLC. L2 Ventures, LLC is the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by L2 Ventures, LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":99513,"source":{"system":"sec-edgar","filing":"0001209191-17-035155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117035155/doc4.xml","form_type":"4"}},{"id":4308452,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-23T16:04:14.000Z","date":"2017-05-22","kind":"purchase","acquired":true,"shares":1100,"price":8,"value":8800.0,"ownership":{"direct":true},"balance_after":3300,"source":{"system":"sec-edgar","filing":"0001209191-17-034602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117034602/doc4.xml","form_type":"4"}},{"id":4375135,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":89684,"kind":"person","name":"SHAFFER CHRISTY L","position":1,"cik":"0001145929","reported_name":"SHAFFER CHRISTY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-22T17:14:12.000Z","date":"2017-03-20","kind":"purchase","acquired":true,"shares":2200,"price":6.9,"value":15180.0,"ownership":{"direct":true},"balance_after":2200,"source":{"system":"sec-edgar","filing":"0001209191-17-022349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1145929/000120919117022349/doc4.xml","form_type":"4"}}]}